lundi 12 juin 2017

Onco Actu du 12 juin 2017

4.1 Dép., diag. & prono. - Prostate

Biomarker Test Could Reduce Unnecessary Biopsies to Detect Prostate Cancer [NCI]

5. Traitements

'Tumor agnostic' cancer drugs seen boosting wider genetic tests [Reuters]

5.12.3 Immunothérapies-combinaisons

A quick look at the axitinib data and IO/VEGF inhibitor combos [SugarCone Biotech]

5.12.5 Immunothérapies - Pharma

Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead? [EndPoints]

5.2 Pharma

Trial observers say ‘game over’ for XBiotech’s failed PhIII cancer study, the latest in a long line of setbacks [EndPoints]

Roche CEO still optimistic on new breast cancer drug [Reuters]

5.2.1 Pharma - Partenariats

Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer [Astellas]

5.2.3 Pharma - économie

Cancer Setback Leaves Bristol-Myers Vulnerable to Takeover [Bloomberg]

5.3 Traitements - FDA, EMA, NICE...

PRAC concludes there is no evidence of a change in known risk of neutropenic enterocolitis with docetaxel [EMA]

5.4 Traitements - Economie

The New War on (Overpriced) Drugs [Wired]

Drug Prices: This Time Is Different [Wall Street Journal]

5.5 ASCO

8 stars: A look back at ASCO spotlights the top cancer drugs to watch, and 1 to forget [EndPoints]

5.5.16 ASCO (médecine de précision)

Routine Molecular Screening of Advanced Refractory Cancer Patients [ESMO]

5.9.3 EHA

AbbVie Announces New Data Evaluating Venetoclax in a Variety of Hematologic Malignancies at the 22nd European Hematology Association Congress [AbbVie]

6.10 Politiques

UK scientists hope for softened Brexit after shock election result [Nature]

Japan government scraps proposals for drug-price cuts in policy guidelines [Reuters]

6.10.1 Politiques (USA)

AACR Applauds Presidential Nomination of Norman (“Ned”) Sharpless, MD, as Director of the National Cancer Institute [AACR]

American Cancer Society Congratulates Norman Sharpless on Appointment as NCI Director [ACS]

Norman “Ned” Sharpless named NCI director by Trump administration [The Cancer Letter]

6.11 Patients

‘How long have I got?’: Why many cancer patients don’t have answers [USA Today]

6.4 Médico-éco

Cutting the NIH budget is bad for health and business [STAT]

6.7.2 Applis

The Paradoxical Benefits Of A Web App For Cancer Patients [Forbes]

6.8 Communication

Got Cancer Questions? This Little-Known Hotline Is Here To Help [NPR]

6.9 Controverses

Saying Los Angeles lacks a great cancer center, Soon-Shiong plans to open one [STAT]